Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vistagen Therapeutics (VTGN) Change in Accured Expenses (2016 - 2025)

Vistagen Therapeutics' Change in Accured Expenses history spans 14 years, with the latest figure at $294000.0 for Q4 2025.

  • For Q4 2025, Change in Accured Expenses fell 85.14% year-over-year to $294000.0; the TTM value through Dec 2025 reached $4.0 million, down 13.27%, while the annual FY2025 figure was $5.7 million, 988.31% up from the prior year.
  • Change in Accured Expenses for Q4 2025 was $294000.0 at Vistagen Therapeutics, down from $3.2 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $3.7 million in Q3 2021 and bottomed at -$2.4 million in Q2 2025.
  • The 4-year median for Change in Accured Expenses is $1.2 million (2024), against an average of $1.1 million.
  • The largest annual shift saw Change in Accured Expenses soared 674.79% in 2021 before it plummeted 432.75% in 2025.
  • A 4-year view of Change in Accured Expenses shows it stood at $3.7 million in 2021, then plummeted by 92.71% to $269000.0 in 2023, then surged by 635.32% to $2.0 million in 2024, then crashed by 85.14% to $294000.0 in 2025.
  • Per Business Quant, the three most recent readings for VTGN's Change in Accured Expenses are $294000.0 (Q4 2025), $3.2 million (Q3 2025), and -$2.4 million (Q2 2025).